Status:
COMPLETED
18F-fluorocholine PET/CT for Hyperparathyroidism
Lead Sponsor:
Buddhist Tzu Chi General Hospital
Conditions:
Hyperparathyroidism
Eligibility:
All Genders
20-100 years
Phase:
NA
Brief Summary
Hyperparathyroidism is a common endocrine disorder which can result in many severe complications. For patients with hyperparathyroidism, Tc-99m sestamibi imaging is the major imaging tool for pre-oper...
Detailed Description
The investigators conducted a prospective study to investigate the performance of 18F-choline (FCH) PET/CT and 99mTc- sestamibi scintigraphy in the pre-operative localization of hyperfunctioning parat...
Eligibility Criteria
Inclusion
- Patients are diagnosed to have hyperparathyroidism based on serum iPTH data (\> 72 pg/mL).
- Planned to undergo surgical resection of the hyperfunctioning parathyroid gland.
- Referred for single isotope dual phase Tc-99m sestamibi scintigraphy.
- The 18F-FCH PET is performed within 6 weeks of the single isotope dual phase Tc-99m sestamibi scintigraphy.
- If premenopausal and sexually active woman, need contraception (tubal ligation, intrauterine devices, or oral contracepts/condom after the last menstrual period till the image exams)
Exclusion
- Surgical management is not considered.
- Younger than 20-year-old.
- Factors that hampers the patient to receive positron emission tomography, e.g., unstable vital signs (shock), conscious disturbance, claustrophobia, etc...
- Allergic to investigaional drug.
- Pregnant or lactating woman.
Key Trial Info
Start Date :
January 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04316845
Start Date
January 16 2018
End Date
December 31 2019
Last Update
August 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hualien Tzu Chi Hospital
Hualien City, Taiwan, 970